PNPLA3 and metabolic dysfunction-associated steatotic liver disease: Overcoming undesirable PNPLA3 phenotype could be achieved via three major approaches, including targeting PNPLA3 with (i) RNA interference, (ii) small molecules, or (iii) interfering NAFLD-related metabolic pathways [184].